Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia. Issue 1 (2017)

• Record Type: Journal Article
• Authors: Aghemo, Alessio; Lunghi, Giovanna; Ravasio, Roberto; Torresani, Erminio; Dionisi, Matteo; Paolini, Davide; Colombo, Massimo
• Is Part Of: Global & regional health technology assessment. Volume 4:Issue 1(2017)
• Publication Date: 2017
• Subjects: Dual or triple therapy -- Cobas Ampliprep/Cobas TaqMan -- HCV-G1 -- Real-Time HCV -- Residual viremia; Medical technology -- Evaluation -- Periodicals; Medical technology -- Economic aspects -- Periodicals; 610
• DOI: 10.5301/grhta.5000248
• Languages: English
• ISSNs: 2284-2403

Abstract

Cost analysis of residual viremia detected by two real-time PCR assays for response-guided (dual or triple) therapy of HCV genotype 1 infection: Introduction: The duration of interferon-based dual and triple therapies for HCV-G1 is determined by assessment of early viral kinetics. We conducted a cost analysis to determine the mean cost of dual or triple therapy treatment for a patient with HCV-G1, where the therapy duration (24 or 48 weeks) is guided by HCV-RNA assay. Methods: HCV-RNA was assessed by two widely used real-time PCR-based assays, Cobas Ampliprep/Cobas TaqMan (CAP-CTM) and Real-Time HCV (ART). As far as the dual therapy (PegINFα-2b and RBV) is concerned, at week 12 of treatment 16.0% of patients (27/169) were eligible to receive a shorter duration of therapy (24 weeks) according to CAP-CTM and 8.9% (15/169) according to ART: 26 patients achieved SVR (15.4%) with CAP-CTM and 15 with ART (8.9%). With regard to triple therapy (TPV, PegINFα-2a and RBV), at week 12 of treatment 59.6% of patients (31/52) were eligible to receive a shorter duration of therapy (24 weeks) according to CAP-CTM and 28.8% (15/52) according to ART: 30 patients achieved SVR (57.7%) with CAP-CTM and 13 with ART (25.0%). The cost analysis was conducted from the perspective of the Italian National Health Service (NHS). Only drug (TPV, PegINFα-2a, PegINFα-2b and RBV) and test (CAP-CTM and ART) costs were taken into account. Ex-factory prices (included all discounts) and national tariffs were used to calculate drug consumptions and tests, respectively. Costs were assessed in Euros 2015. Results: With regard to dual therapy, the overall mean treatment cost per patient with CAP-CTM (€9, 572.77) was lower than with ART (€9, 876.19). With regard to triple therapy, the overall mean treatment cost per patient was lower with CAP-CTM (€31, 354.40) than with ART (€33, 155.26). Conclusions: CAP-CTM HCV-RNA assay was cost-saving from the Italian NHS perspective compared with ART HCV-RNA assay in the dual (-€303.42 per patient) and triple (-€1, 800.96 per patient) HCV therapy.